Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 30.00 | |
10 mg | In stock | $ 47.00 | |
25 mg | In stock | $ 73.00 | |
50 mg | In stock | $ 97.00 | |
100 mg | In stock | $ 147.00 | |
500 mg | In stock | $ 369.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 52.00 |
Description | Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity |
Targets&IC50 | BRAF:28 nM, B-Raf (V600E):19 nM, PDGFRβ:22 nM, Raf-1:2.5 nM, VEGFR1:13 nM, VEGFR3:46 nM, VEGFR2:4.2 nM |
In vitro | Regorafenib inhibits additional angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF. |
In vivo | Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.?In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 hr after the last dosing and correlated with tumor growth inhibition (TGI).?A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.?Regorafenib exhibited potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages observed in breast MDA-MB-231 and renal 786-O carcinoma models.?Pharmacodynamic analyses of the breast model revealed strong reduction in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2[1]. |
Synonyms | BAY73-4506 hydrochloride |
Molecular Weight | 519.28 |
Formula | C21H16Cl2F4N4O3 |
CAS No. | 835621-07-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.6 mg/mL (10.78 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Regorafenib Hydrochloride 835621-07-3 Angiogenesis Apoptosis Autophagy MAPK Tyrosine Kinase/Adaptors PDGFR VEGFR Raf c-RET Raf kinases inhibit Inhibitor RET BAY73-4506 Hydrochloride Vascular endothelial growth factor receptor Regorafenib BAY 73-4506 BAY73-4506 hydrochloride Platelet-derived growth factor receptor inhibitor